ABSTRACT
Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.
Subject(s)
Antineoplastic Agents/adverse effects , Atrial Fibrillation/etiology , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Protein Kinase Inhibitors/adverse effects , Pyrazoles/adverse effects , Pyrimidines/adverse effects , Adenine/analogs & derivatives , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Atrial Fibrillation/diagnosis , Atrial Fibrillation/therapy , Disease Management , Female , Hemorrhage/diagnosis , Hemorrhage/etiology , Hemorrhage/therapy , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Male , Middle Aged , Piperidines , Protein Kinase Inhibitors/therapeutic use , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , Retrospective StudiesABSTRACT
Only a minority of chronic lymphocytic leukemia (CLL) patients harboring a positive direct antiglobulin test (DAT) will develop autoimmune hemolytic anemia (AIHA). In a single institution cohort of 378 CLL patients, 56 patients (14.8%) had at least one positive DAT during the course of the disease, either at diagnosis or later. We found no relationship between the time of the first positive DAT and overall survival (OS). However, patients with a positive DAT who did not develop AIHA had the same adverse outcome as patients who developed AIHA. Of the patients who were in Binet stage A at diagnosis, those with a positive DAT had a significantly shorter OS, regardless of their IGHV mutational status, however, there was a strong association with VH1-69. By multivariate analysis, a positive DAT was found to be an independent adverse prognostic factor for OS. Thus, DAT represents a strong adverse prognostic factor and its determination should be repeated during follow-up.
Subject(s)
Anemia, Hemolytic, Autoimmune/diagnosis , Coombs Test , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Adult , Aged , Aged, 80 and over , Anemia, Hemolytic, Autoimmune/etiology , Anemia, Hemolytic, Autoimmune/immunology , Anemia, Hemolytic, Autoimmune/mortality , Cohort Studies , Complement C3d/analysis , Data Interpretation, Statistical , Disease Progression , Disease-Free Survival , Female , Follow-Up Studies , Humans , Immunoglobulin G/blood , Kaplan-Meier Estimate , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/mortality , Male , Middle Aged , Predictive Value of Tests , PrognosisABSTRACT
Immunocompromised individuals such as patients with chronic lymphocytic leukemia (CLL) are at risk of impaired immune responses to vaccination. The objective of our study was to evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses in patients with CLL after the first, second, and third doses of the BNT162b2 or mRNA-1273 vaccines and after a single dose for patients with confirmed previous COVID-19. In all, 530 patients were included in the study. Patients received 2 doses at a 4-week interval and a third dose if they were seronegative after the second dose. Response rate was 27% after dose 1 and 52% after dose 2. Post-dose 2 treatment-naïve patients had the highest response rate (72%) followed by patients previously treated by chemoimmunotherapy (60%). Among patients receiving therapy, those receiving Bruton tyrosine kinase inhibitor alone (22%) or in combination with anti-CD20 monoclonal antibodies or venetoclax (0%) had the poorer response rate whereas patients who received venetoclax monotherapy achieved a significantly higher response rate (52%). A multivariable analysis identified age older than 65 years, ongoing CLL treatment, and gamma globulin ≤6 g/L as independent predictors of the absence of seroconversion. Post-dose 2 seronegative patients had a global response rate of 35% after dose 3. This study provides an argument for the use of a third dose and for prophylactic SARS-CoV-2 neutralizing monoclonal antibodies.
Subject(s)
COVID-19 , Leukemia, Lymphocytic, Chronic, B-Cell , 2019-nCoV Vaccine mRNA-1273 , Aged , Antibodies, Viral , BNT162 Vaccine , COVID-19 Vaccines , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , RNA, Messenger/genetics , SARS-CoV-2ABSTRACT
Around 20% of Hodgkin lymphoma (HL) patients are refractory to first-line therapy with ABVD (adriamycin-bleomycin-vinblastine-dacarbazine) or relapse after complete remission. Salvage regimens frequently have delayed courses or require dose-reduction because of haemotoxicity. We evaluated the IVOx (ifosfamide-etoposide-oxaliplatin) salvage regimen in terms of response rate, toxicity and stem-cell mobilization. Thirty-four patients with relapsed/refractory HL after anthracycline-containing chemotherapy prospectively received IVOx, consisting of ifosfamide (1500 mg/m(2) days 1-3), etoposide (150 mg/m(2) days 1-3) and oxaliplatin (130 mg/m(2) day 1). Patients <65 years old received high-dose therapy followed by autologous stem-cell transplantation (HDT-ASCT). Response was assessed by computed and positron-emission tomographies. Overall and complete response rates were 76% and 32%, respectively, after 2 cycles. Three episodes of febrile neutropenia occurred, and three patients required dose-reductions. Twenty-six patients underwent HDT-ASCT. With median follow-up at 5 years, the 5-year overall and event-free survival rates were 74% and 63%, respectively. IVOx is a well-tolerated outpatient regimen for relapsed HL, that does not hamper stem-cell mobilization, achieves good response rates and compares favourably with previously published salvage regimens.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Etoposide/administration & dosage , Hodgkin Disease/mortality , Hodgkin Disease/prevention & control , Ifosfamide/administration & dosage , Organoplatinum Compounds/administration & dosage , Stem Cell Transplantation , Adolescent , Adult , Aged , Bleomycin/administration & dosage , Dacarbazine/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Epirubicin/administration & dosage , Female , Follow-Up Studies , Humans , Male , Middle Aged , Oxaliplatin , Prospective Studies , Recurrence , Survival Rate , Transplantation, Autologous , Vinblastine/administration & dosageSubject(s)
Blood Transfusion , Hematopoietic Stem Cell Transplantation/methods , Neoplasms/therapy , Adult , Contraindications , Feasibility Studies , Female , Hematopoiesis , Humans , Jehovah's Witnesses , Male , Middle Aged , Religion and Medicine , Transplantation Conditioning/methods , Treatment Outcome , Young AdultSubject(s)
Lymphoma, Non-Hodgkin/complications , Purpura, Thrombocytopenic, Idiopathic/complications , Purpura, Thrombocytopenic, Idiopathic/drug therapy , Receptors, Fc/therapeutic use , Receptors, Thrombopoietin/agonists , Recombinant Fusion Proteins/therapeutic use , Thrombopoietin/therapeutic use , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Female , Humans , Lymphoma, Non-Hodgkin/drug therapy , Male , Salvage Therapy , Treatment OutcomeSubject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Leukemia, Monocytic, Acute/complications , Leukemia, Myelomonocytic, Acute/complications , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/chemically induced , Acute Disease , Adult , Fatal Outcome , Female , Flow Cytometry , Humans , Immunophenotyping , Leukemia, Monocytic, Acute/drug therapy , Leukemia, Myelomonocytic, Acute/drug therapy , Male , Middle Aged , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy , Remission InductionABSTRACT
Follicular lymphomas (FLs) are frequent B-cell derived malignancies, generally demonstrating an indolent evolution. Although circulating FL cells may be detected by high-resolution analysis, bloodstream involvement by FL cells is unusual. We observed in 10 patients a leukemic phase of FL at the onset of the disease. Six of them had concomitant lymph node involvement and all of them required treatment at diagnosis due to a high tumor burden, whereas four patients had pure FL-cell leukemia, which was associated with a more indolent clinical outcome. The detection of a leukemic phase should therefore be studied as a potential prognosis marker in further studies.